PharmaJet, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-06-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.pharmajet.com
Clinical Trials
7
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
- Conditions
- Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy VolunteersSARS CoV-2
- Interventions
- Biological: COMIRNATY®
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06919796
- Locations
- 🇺🇸
Hope Clinic of the Emory Vaccine Center Division of Infectious Diseases, Department of Medicine, School of Medicine, Decatur, Georgia, United States
Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System
- Conditions
- Vaccine Reaction
- Interventions
- Device: PharmaJet Tropis® Needle-Free Injection SystemDevice: PharmaJet Stratis® Needle-Free Injection System
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- PharmaJet, Inc.
- Registration Number
- NCT06142461
- Locations
- 🇮🇩
Universitas Padjadjaran, Bandung, Indonesia
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
- Conditions
- Vaccine Reaction
- Interventions
- Device: PharmaJet Tropis Needle-free Injection SystemDevice: PharmaJet Stratis Needle-free Injection System
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT06002503
- Locations
- 🇺🇸
Velocity Clinical Research, Cincinnati, Ohio, United States
Inactivated Influenza Via Jet Injection
- Conditions
- Influenza, Human
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 985
- Registration Number
- NCT02290691
- Locations
- 🇺🇸
Optimal Research LLC, Huntsville, Alabama, United States
🇺🇸Optimal Research, LLC, Rockville, Maryland, United States
🇺🇸Optimal Reserach, LLC, Mishawaka, Indiana, United States
Jet Injection for Influenza
- Conditions
- Influenza, Human
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 1250
- Registration Number
- NCT01688921
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸University of Colorado Health Harmony Campus, Fort Collins, Colorado, United States
🇺🇸Medical Center of the Rockies, Loveland, Colorado, United States
- Prev
- 1
- 2
- Next
News
Immuno Cure Partners with PharmaJet to Advance HIV Therapeutic DNA Vaccine Using Needle-Free Delivery Technology
Immuno Cure and PharmaJet signed a collaboration agreement to evaluate the HIV therapeutic DNA vaccine ICVAX using PharmaJet's needle-free Tropis intradermal delivery system in clinical trials.
Needle-Free Drug Delivery Devices Market Set to Reach $5+ Billion by 2035
The needle-free injection system market is projected to grow at a CAGR of 4% from $606 million in 2024 to 2035, driven by increasing chronic disease prevalence and patient preference for painless administration.
PharmaJet's Needle-free Delivery System Shows Promise for African Immunization Programs
• PharmaJet's Tropis needle-free delivery system has demonstrated significant benefits in routine immunization programs across multiple African countries, including Nigeria, Somalia, and Pakistan. • The company will showcase its innovative needle-free intradermal delivery technology at the upcoming Ethiopian Medical Association's 61st Annual Medical Conference in February 2025. • Clinical evidence from multiple countries supports the effectiveness of PharmaJet's technology, particularly in mass vaccination campaigns and routine immunization programs.